Verastem Taps LabCorp to Validate Companion Dx for Cancer Stem Cell Agent | GenomeWeb

NEW YORK (GenomeWeb News) – Verastem said today that Laboratory Corporation of America will help it validate biomarkers that could be used to develop a companion diagnostic for a Verastem drug candidate, the focal adhesion inhibitor VS-6063.

The biomarkers will be used in clinical studies in ovarian cancer and mesothelioma, including a potentially pivotal study of VS-6063 in mesothelioma expected to commence later this year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."